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Abstract    
Objective 
Cryoglobulinemic vasculitis (CV) involving small- and medium-sized vessels is very 
frequently associated to hepatitis C virus and may be responsible for multiple organ 
involvement, including skin ulcers (SU). These latter are often non-healing cutaneous lesions, 
possibly complicated by local infection and gangrene; they may severely affect the patients’ 
quality of life and the overall prognosis. Therefore, the treatment of cryoglobulinemic SU is 
particularly challenging in the clinical practice. 
The present work evaluated the prevalence and correlations of cryoglobulinemic SU with other 
clinico-epidemiological features of CV; moreover, our long-term experience with the 
management strategies of these cutaneous lesions was compared with the world literature on 
this topic. 
 
Methods 
The study included 126 CV patients (24 M and 102 F, age 69±11.2SD years, disease duration 
7±6.9SD years), followed at our Rheumatology Unit during the last decade. All patients were 
carefully evaluated as regards the entire cryoglobulinemic syndrome with particular concern for  
clinical characteristics and treatment of SU. 
 
Results 
Among 126 CV patients 36 individuals (29%) experienced at least one episode of SU, more 
commonly localized at the lower limbs. Patients with complicating SU showed significantly 
higher percentage of purpuric manifestations (p <0.01), liver (p <0.001), peripheral nerve (p 
<0.02), and/or thyroid involvement (p 0.019). 
Therapeutic approach to SU included both systemic (immunosuppressors, corticosteroids, 
and/or plasma exchange) and local treatments. These latter consisted of sharp or surgical 
debridement as well as interactive dressing according to the condition of wound bed, 
perilesional skin, and the possible presence of infection, detected in 29/36 (81%) of individuals. 
Al patients underwent to analgesic treatment for SU-related background pain as well as 
procedural pain, which was critical for an effective local SU management. 
The large majority of SU healed in a variable time interval according to severity of the single 
lesion; only 5 patients with very severe, non-healing SU needed amputation. 
The updated review of the literature revealed the presence of SU in around a quarter of CV 
patients. Among systemic treatments, the anti-CD20 monoclonal antibody, rituximab, 
represents one of the most effective and frequently employed therapies; while available data 
focusing on local therapeutic approach are generally limited to anecdotal observations. 
 
Conclusions 
On the whole, the treatment of cryoglobulinemic SU should be tailored on the single patient’s 
conditions using combined systemic and local treatments; lesional sharp debridement and 
interactive dressing as well as procedural pain management were decisive, particularly for more 
severe, non-healing cutaneous lesions. 
  
 
 
Introduction 
Mixed cryoglobulinemia syndrome (MCs) is a systemic vasculitis characterized by multiple 
organ involvement due to the vascular deposition of immune-complexes, mainly the 
cryoglobulins (1-7). The term cryoglobulinemic vasculitis (CV) is frequently used as synonym. 
B-lymphocyte expansion represents the underlying pathological alteration frequently triggered 
by hepatitis C virus (HCV) infection (6-9). 
Leukocytoclastic vasculitis is the histopathological hallmark of CV; it may involve small- and 
medium-sized vessels and may be responsible for multiple organ involvement (1-7). According 
to its first description as autonomous disorder (1), MCs is characterized clinically by a triad -
purpura, weakness, arthralgias- and by a series of pathological conditions, including chronic 
hepatitis, membranoproliferative glomerulonephritis (MPGN), peripheral neuropathy, skin 
ulcers, diffuse vasculitis, and, less frequently, by lymphatic and hepatic malignancies (1-8). 
The presenting symptoms largely vary among MCs patients; at the initial observation, they 
show different clinico-serological patterns, varying from apparently isolated serum mixed 
cryoglobulins to complete cryoglobulinemic syndrome. 
The skin lesions, in particular the orthostatic purpura, represent the most frequent 
manifestations that may appear at any time during the clinical course of MCs (1-7). Purpuric 
manifestations are generally intermittent, while their dimension and diffusion largely varied, 
from sporadic isolated petechias to severe vasculitic lesions, often complicated by torpid skin 
ulcers (SU), generally localized to lower and/or upper limbs, including distal necrosis of hands 
and feet. (Fig 1). They are the direct consequence of vasculitic alterations with the possible 
contributions of various co-factors, in particular chronic venous insufficiency, physical stress, 
mainly the prolonged standing, and/or muggy weather (5-7). In addition, the contribution of 
hemorheological disturbances due to high cryocrit levels may also be taken in account.  
The treatment of cryoglobulinemic SU is particularly challenging. Cutaneous manifestations 
are prevalent in the lower limbs, where the above-mentioned pathogenetic co-factors may be 
concurrent, more often in patients receiving long-term steroid treatment; but they may also 
affect other cutaneous areas of the extremities such as fingers and toes (6, 7). SU are painful, 
non-healing, and often complicated by local infection; moreover, they may severely affect the 
patients’ quality of life. Systemic treatments of MCs with/without SU, directed at improving 
the immune-system alterations of and/or HCV eradication, are largely reported in the world 
literature (5-16); while, specific therapeutic strategies of cryoglobulinemic SU, particularly 
with regards to local treatments that can be decisive for the most severe lesions, are poorly 
addressed (5-16). 
The present study focused on the clinico-epidemiologic characteristics and management 
strategies of cryoglobulinemic SU in a large series of MCs patients followed at our 
Rheumatology Unit. In addition, the observed findings were compared to those emerging from 
the updated review of the literature on this topic. 
 
 
Patients and Methods 
 
The study evaluated 126 patients with CV (24 M and 102 F, age 69±11.2SD years, disease 
duration 7±6.9SD years), followed at our Rheumatology Unit during the last decade and 
classified according to the current criteria (5, 6, 17). Demographic and clinico-serological 
features of all MCs patients were evaluated according to previously reported methods (5 ,6; 
Tab.1). According to their localization, SU comprise two main types of lesions, namely distal 
necrotic wounds of the digits and toes and cutaneous ulcers of lower limbs (Fig. 1a: orthostatic 
purpura, b: digital U, c: SU of lower limbs, d: SU of toes). The evaluation of SU included the 
  
number, size, and depth of lesions, wound-bed conditions, presence of granulation tissue, 
exudates, necrosis, and/or infection (18, 19). In the presence of perilesional erythema, swelling, 
abundant purulent exudates, and/or distinctive odor, suggesting possible bacterial infection, 
microbiological examinations were also performed by means of wound swabs. In addition, 
patient self-evaluation of SU-related pain was performed using a visual analogue scale (VAS, 
range 0-10). In all cases the therapeutic strategy included systemic and local treatments tailored 
to individual clinical status (6-16). Systemic treatments were decided according to the 
severity/activity of the whole MCs, including SU and possible comorbidities, and generally 
based on combined corticosteroids (CS), cyclophosphamide (CPX), low antigen-content diet 
(LAC-diet), rituximab (RTX), and/or antivirals (6-16; Fig. 2, 3). Finally, the treatment of SU-
related chronic pain and procedural pain was necessary in all cases in order to improve the 
patients quality of life as well as their compliance to local wound care (Fig. 3; 20). 
Local treatment was regularly performed according to wound bed preparation of the European 
Wound Management Association and the World Union of Wound Healing Societies’ consensus 
statements (18, 19). The wound bed preparation is summarized in the acronymous TIME (18, 
19), which usefully recall to the most important aspects of ulcer evaluation and management: 
necrotic tissue, infection/inflammation, moisture balance, epitelization (Fig. 3). To obtain the 
best results from wound bed preparation, we used active dressing; these medications actively 
interact with the wound tissues in developing of cellular matrix and promoting the entire 
healing process. Among the huge number of available active medications, their use was defined 
in the course of wound management according to careful clinical evaluation of the single 
lesion. The most used products in our experience were the alginate (non-woven absorbent fiber 
derived from different types of algae and seaweeds), hydrocolloid (wafer type of self-adhering 
dressing containing gel-forming agents in an adhesive compound laminated onto a flexible, 
water-resistant outer layer), hydrofiber (soft, sterile, non-woven pad or ribbon dressing 
composed of sodium carboxymethylcellulose), hydrogel (water based-gel wafer able to 
promote moist environment and removal of necrotic tissue through autolytic debridement), and 
polyurethane foam or film (open-cell hydrophilic polyurethane foam sheets, permeable to gas 
and water vapor, with an hydrophobic surface).  
The CV-related SU refractory to conventional therapies were usefully treated by means of growth 
factors as the homologous platelet gel (21, 22). Finally, for more severe and hard-to-heal skin 
lesions, skin grafting, skin bank bioproducts, especially cyropreserved skin and de-epidermized 
dermis (DED) and/or others skin substitutes were used (23). Since SU complicating CV are 
extremely painful, adequate pain control was carried out (24-29).  In all 36 CV patients with skin 
wounds a long-lasting analgesic treatment for chronic pain, usually defined as background pain, 
was done by means of opioids (oral oxycodone) and pregabalin. The procedural pain was treated 
with topical application of lidocaine/prilocaine cream (EMLA) for skin ulcers with mild pain (VAS 
<5), while the addition of local ± oral morphine was necessary to treat the more severe lesions 
(VAS >5) (29). In all cases, a team of operators with specific experience carried out such integrated 
therapeutic approach. 
 
Review of the literature.  A PubMed search up to March 2014, with the key words 
‘cryoglobulinemic skin ulcers’, ‘cryoglobulinemic vasculitis’, ‘mixed cryoglobulinemia’, ‘mixed 
cryoglobulinaemia’,  ‘cryoglobulinemic skin involvement’, and ‘skin ulcer treatment’ was done at 
PubMed, Scopus, Thomson Reuters’ Web of Science, EMBASE, Asian Science Citation Index 
(ASCI), and IndMed. 
to find published clinical studies and case reports regarding patients with CV complicated by 
SU.  
  
 
 
Results.  
Clinico-serological features of our MCs patients with/without SU are shown in Tab. 1. Out of 
126 MCs patients 36 individuals (29%) experienced at least one episode of SU localized at the 
lower limbs; in addition, 9/36 (25%) patients developed at least one episodes of digital SU 
(Tab. 2). Recurrent episodes characterized by one or multiple skin lesions were observed in the 
majority of individuals (31/36, 86%). Skin lesions were more frequently found in males (38%) 
than in females (26%).  
Moreover, one or more episodes of infected SU were observed in 29/36 (81%); the involved 
infectious agents were S. Aureus in 55% of cases, P. Aeruginosa and Enterobacter in 24 and 
21%, respectively. The 36 MCs patients with complicating SU revealed some interesting 
peculiarities if compared to MCs patients without (Tab. 1); in particular, they showed a 
significantly higher percentage of purpuric manifestations (p <0.01), liver (p <0.001), 
peripheral nerve (p <0.02), and/or thyroid involvement (p 0.019).  
In all 36 patients with cryoglobulinemic SU the therapeutic strategy was based on combined 
systemic and local therapies, including pain treatment (Tab. 2; Fig. 2, 3).  
 
Systemic treatment. Systemic treatment in patients with SU was decided according to same 
therapeutic strategies usually followed for the whole MCs with some specific modifications 
(Fig. 2, 3). The treatment of MCs may be carried out at three different levels: a) the etiological 
treatment of HCV-associated MCs is directed at the eradication of chronic HCV infection; b) 
the pathogenetic therapies, able to reduce the autoimmune-lymphoproliferative alterations, 
mainly B-lymphocyte expansion and autoantibodies production; and c) 
pathogenetic/symptomatic therapies in order to improve the tissue lesions due to immune-
complex-mediated cryoglobulinemic vasculitis (5-16; Fig. 2). Tab. 2 reports the different 
therapies employed in our 36 cryoglobulinemic patients with SU, in all cases as combined 
treatment tailored to the single patient on the basis of the activity/severity of MCs and 
comorbidities. Furthermore, in 29 patients developing one or more episodes of infected SU 
systemic antibiotic regimens were necessary. 
 
Local therapy. Local therapy of single SU was invariably performed according to the wound 
bed preparation procedures (19, 20; Fig. 3). Each lesion was preliminarily treated with topical 
anesthetic EMLA to reduce the procedural pain; moreover, in patients with pain VAS >5 the 
use of both local and systemic morphine was necessary (29). Sharp or surgical debridement 
was performed in all cases; while interactive dressing was decided after a careful evaluation of 
the condition of wound bed, perilesional skin, and the possible presence of infection. In some 
cases (22%) a sensibilization reaction to dressing medications with erythema and itch in 
perilesional skin were observed.  
Among 36 patients with SU 18 individuals developed a very severe episode of SU of the lower 
limbs unresponsive to the above-described systemic and local treatments. Therefore, in 14/18 
SU dermal equivalent or autologous skin grafting were used as adjunctive therapy to 
conventional local treatment; namely, 12/14 SU were treated with composite grafts from skin 
bank consisting of DED, followed by complete resolution of the lesions in 5 and a marked 
improvement in others 3; while 4 lesions showed an initial improvement complicated by local 
infection requiring multiple skin implants and prolonged antibiotic therapy. In 2/14 with wider 
SU autologous skin grafting was able to improve the skin wounds.  
Finally, in the other 4/18 non-healing SU an attempt with local homologous platelet gel was 
decided, followed by complete healing in one case and a marked improvement in two, while 
the fourth lesion was complicated by severe infection (P. Aeruginosa), requiring long-term 
systemic antibiotic therapy. 
  
 
Analgesic treatment. Patients with skin lesions were invariably treated with analgesics for 
background pain (Fig. 3); according to patient’s pain VAS, referred to the most painful lesion 
in the presence of multiple lesions. In the presence of mild pain VAS (≤4) the SU was usefully 
treated with paracetamol  (1g x 2/day) or tramadol (150mg/day), while for moderate-severe 
pain VAS (>4) scores combined treatment with opioids (oral oxycodone, medially 20mg/day,) 
and pregabalin (medially 300mg/day) was necessary. Finally, SU associated to severe pain 
scores (VAS 9-10/10) required adjunctive oral morphine (5mg/day sublingual morphine 
sulphate, Oramorph).  
Before each session of local management, lesions were invariably treated with the application 
of EMLA as above mentioned; a good compliance during the entire session of debridement and 
dressing was observed mainly in patients with cutaneous lesions characterized by mild pain 
VAS at baseline. While, procedural management of SU in patients with pain VAS >4 needed a 
combined therapy of EMLA and local morphine, or both local and oral morphine, according to 
the previously described timing of procedural pain management (29). In only two individuals 
with particularly severe SU, complicated by infection and gangrene, procedural analgesic 
treatment needed to be integrated with IV morphine (29).  
In all instances, analgesic treatments of background and procedural pain revealed manageable 
and well tolerated, in no cases sensitization phenomena were observed. 
On the whole, the majority of SU healed, even if the positive outcome was obtained in a 
variable time interval according to the severity of the single lesion and after one or more 
attempts of combined therapies. Generally, the healing of small and superficial wounds was 
followed by complete re-epithelialization, while the healing of particularly severe SU lead to 
more or less extensive skin scar. Only five patients with very large lesions of the lower limbs, 
complicated by gangrene and local infection, needed surgery at different levels: in two cases 
through-the-knees amputation, distal of ankle in one, and single toe amputation in the other 
two. 
 
 
Review of the literature. As regards the prevalence of SU in MCs patients, available data are 
limited to 11 clinical reports published in the world literature, often characterized by relatively 
small patients series with frequent contrasting findings (Tab. 3). In these cohort studies (2-4, 7, 
8, 30-35), the reported prevalence of SU ranged widely, from 4.7 to 30% of MCs patients. In 
our large series of 231 patients observed for a long-term follow-up period (7) this complication 
affected a significant proportion of individuals (22%).  
Similarly, data regarding the therapeutic approach to SU complicating CV included 46 studies 
(11, 14, 16, 36-78, Tab. 4); only 13 reports regards to CV patients’ series (11, 14, 16, 36-45), 
while the majority (no. 33) describes anecdotal observations of single cases (28/33) or very 
small series of 2-5 patients (5/33). The patients’ clinico-epidemiological and virological 
features are not available in all reports; these patients’ series were characterized by serum type 
II mixed cryoglobulins and HCV seropositivity in the majority of cases (Tab. 4). Considering 
the 13 cohort studies (11, 14, 16, 36-45), the prevalence of SU widely ranged from 12.5 to 
50%, it was medially higher compared to the cohort studies reported in Tab. 3. This 
discrepancy may reflect a selection bias due to the recruitment for therapeutic trials of patients 
with more severe MCs, including the SU. The first 13 studies (Tab. 4) were generally carried 
out during the last decade. The employed systemic treatments are largely variable; however, the 
use of rituximab, alone or in combination with antivirals represents the most frequent 
therapeutic approach, i.e. 12/13 studies. Almost invariably they were retrospective studies 
reporting the effect of systemic treatments in patients consecutively enrolled in single referral 
centers or as multicenter study in one case (11). In only one controlled trial a higher prevalence 
of SU healing was observed in the group of patients treated with rituximab compared to those 
  
treated with other therapies (45). Of note, the local treatments were never mentioned in these 
cohort studies (11, 14, 16, 36-45). Similarly, only 10/28 anecdotal observations (49, 51, 55, 60, 
62, 64, 66, 67, 70, and 78) reported local treatments of SU, more often without detailed 
information. With regards the outcome of SU, the employed treatments were generally 
followed by the healing of cutaneous lesions, while amputation was observed in only one case. 
 
 
Discussion 
The present study firstly focused on one of the most challenging complications of 
cryoglobulinemic vasculitis by reporting our long-term experience in the management of SU in 
patients with MCs, as well as by analyzing the world literature on this topic. 
In a large series of MCs patients enrolled at our rheumatology unit during the last decade one 
or more episodes of SU were recorded in almost one third of individuals, more frequently in 
males; the large majority of patients developed recurrent, difficult to heal, and often multiple 
skin lesions. These complications were significantly more frequent in patients with clinically 
severe purpuric manifestations, liver, peripheral nerve, and/or thyroid involvement, as well as 
in the serological subset of type II mixed cryoglobulinemia. On the whole, the association of 
recurrent SU with other important clinical symptoms seems to characterize a more aggressive 
clinical variant of CV. The majority of SU were localized to lower limbs and frequently 
complicated by local infections; both conditions may make more difficult the management of 
cutaneous lesions, which per se are scarcely responsive to various treatments. Following the 
experience of other specialties regarding the treatment of non-healing SU such as diabetes-
associated manifestations (18-21), we tried to develop during the years a holistic therapeutic 
strategy to cryoglobulinemic SU. It was based on the careful patient’s assessment of the whole 
MCs (6, 7, 11), as well as of local characteristics of the single skin lesion, and the presence of 
systemic and local comorbidities (diabetes, other endocrine, metabolic, peripheral artero-
venous involvement, and/or infections, etc.). In all instances, systemic treatment was tailored 
on the single patient using antiviral and/or pathogenetic-symptomatic therapies (6-17); these 
latter were employed, generally as multiple drug therapy, namely, immunosuppressors, 
steroids, and/or plasma exchange (6-17). Among pathogenetic treatments the use of anti-CD20 
monoclonal antibody, rituximab, alone or as combined/sequential treatment, can be regarded as 
the most useful and manageable drug (10-17). In all cases of CV complicated by SU the 
combination of systemic and local treatments was necessary; rather, our experience suggested 
that in patients with more severe, resistant lesions the intensive local therapeutic approach may 
be decisive to the healing of the lesions, or at least to avoid or to limit the most dangerous 
consequences of SU such as gangrene and amputation. Local treatment was mainly based on 
the standard procedures of wound bed preparation that permit the sharp or surgical debridement 
(18-29); this latter are critical for the overall outcome of the lesions. The removal of necrotic 
and devitalized tissue, slough and fibrin from the ulcer limits the risk of infections and 
promotes the growth of granulation tissue that is essential for the healing process (18-29). The 
interactive dressing may comprise different medications, including the use of dermal equivalent 
or autologous skin grafting in the largest lesions, and/or homologous platelet gel in SU 
particularly difficult to treat. The use of homologous platelet gel in the treatment of CV-related 
SU revealed useful to obtain a rapid growth of granulation tissue and progress of the wound 
edge (21, 22). In all cases, a careful evaluation, including microbiological swab analysis, of 
possible infectious complications was carried out in order to decide the correct systemic 
antibiotic therapy. Even if healing represents the major purpose of treatment, the management 
of cryoglobulinemic SU-related pain has been identified as a major issue (25-29); a valuable 
analgesic treatment was employed in all cases according to both patients’ pain VAS and 
objective difficulties of the single lesion. Analgesic therapies were mainly directed to improve 
the SU-related background pain as well as the procedural pain (29). The first one can be 
  
particularly difficult to control in those patients with concomitant neuropathic pain due to the 
peripheral neuropathy that frequently complicated the MCs (6, 7); while the management of 
procedural pain was critical in order to permit a valuable wound bed preparation, specially the 
debridement and dressing of the lesion (29). 
The analysis of the world literature on these challenging complications of MCs revealed a 
limited number of clinical studies reporting the prevalence of SU (2-4, 7, 8, 30-35). Among 
available clinical cohort studies, often relatively small patients series, data on the prevalence of 
SU in MCs are generally contrasting; the reported prevalence ranged from 4.7 to 30% of 
cryoglobulinemic patients (2-4, 7, 8, 30-35). The largest patients series with longer follow-up 
period (7) showed the presence of SU in a significant proportion of individuals, suggesting that 
this complication may affect at least a quarter of patients.  
Data regarding the treatment of cryoglobulinemic SU are generally scarce, particularly as 
regards the description of specific local treatments (11, 14, 16, 36-45). In both cohort studies 
and anecdotal reports, the treatment of SU is frequently cited in the context of the therapeutic 
approach to the whole MCs. 
The etiopathogenesis of SU may recognize the same process involved for other clinical 
manifestations of the MCs (5-9). Firstly, the immune-complex mediated leukocytoclastic 
vasculitis involving small vessels, i.e. arterioles, capillaries, and venules, is the main 
pathological alteration responsible for vascular injury and consequent ischemic lesions (5-9). 
Moreover, a number of other co-factors may contribute to the development SU, namely the 
macrovascular involvement, more often the venous chronic failure of the lower limbs, the long-
term steroid treatment with metabolic and cutaneous alterations, and other factors such as long-
standing posture and/or muggy weather (6, 7). In our five patients with severe SU needing 
amputation the above co-factors were particularly evident, mainly the presence of large-
medium sized arteriopathy. Only one comparable case is reported in the literature (67). 
The treatment of MCs is particularly complex due the coexistence of infectious, autoimmune, 
and lymphoproliferative alterations (6-17). This multifaceted disorder is characterized by 
unpredictable clinical course, characterized by alternating periods of disease remission or 
scarce activity and sudden exacerbation or possible neoplastic complications  (6-7). In this 
context the appearance of SU, often resistant to systemic treatments, may further complicate 
the therapeutic approach and severely affect the patient’s quality of life. Therefore, local 
treatment of cryoglobulinemic SU with advanced wound management algorithm may optimize 
the overall therapeutic approach of MCs. 
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Legend to the Figures  
 
Fig. 1     
Cryoglobulinemic vasculitis (CV) complicated by different skin manifestations:  
a) orthostatic purpura secondary to necrotizing leukocytoclastic vasculitis of the skin;  
b) symmetrical hyperpigmentation of the skin on the legs after repeated episodes of purpura; 
both orthostatic purpura and these permanent ochraceous lesions represent the typical skin 
manifestations of CV;  
c)  more severe vasculitic manifestations showing multiple skin ulcers with the presence of 
central necrotic tissue and slough  (adherent fibrous material derived from proteins, fibrin 
and fibrinogen) in the wound bed. The presence of devitalized tissue acts as a physical 
barrier to epidermal cell migration and healing process; the borders of skin ulcers are 
irregular and scarcely reactive.  
d) superficial cutaneous lesions coexist with a severe skin  ulcer extremely painful. The necrotic 
tissue appears as a moist, yellow area with central dry black scar. Reddish and swollen borders, 
representing the first sign of skin tissue destruction, surround the wound until 
metatarsophalangeal skin areas.  
e) distal gangrene of the third finger of the right hand is associated with infected area under the 
necrotic tissue. The progression of the gangrene was treated with aggressive combined therapy   
leading to complete resolution of the vasculitic lesion. 
f) confluent severe non-healing skin lesions were ultimately complicated by gangrene of the 
distal foot. A red line on the skin delimiting the necrotic tissue characterized the areas of 
gangrene. It became progressively dark, while the presence of both necrotic tissue and 
fibrin under the gangrene contributed to local infection. Combined systemic and local 
treatments did not affect the progression of these severe skin lesions needing below-the 
ankle amputation. 
 
 
  
 
  
 
Fig. 2 
The therapeutic strategies to mixed cryoglobulinemic syndrome (MCs) or cryoglobulinemic 
vasculitis should be decided on the basis of the etiopathogenetic cascade that leads from 
hepatitis C virus (HCV) infection to multiple immune-system alterations, mainly the B-cell 
proliferation, and lastly to autoimmune manifestations such as small vessel cryoglobulinemic 
vasculitis secondary to vessel deposition of circulating immune-complex (CIC), mainly mixed 
cryoglobulins. This latter may be complicated by malignancies, mainly B-cell lymphoma. In 
this scenario, MCs can be treated at 3 different levels by means of etiological, pathogenetic, 
and symptomatic therapies. The antiviral therapy aims to eradicate the HCV; it represents the 
etiological treatment of patients with HCV-associated MCs. The anti-CD20 monoclonal 
antibody (rituximab) can be considered the most useful and safe pathogenetic treatment of 
cryoglobulinemic vasculitis. In selected patients with active clinical manifestations the 
sequential or combined therapy with antivirals and rituximab can be usefully employed. Cycles 
of low-dosage corticosteroids may be sufficient in patients with mild manifestations such as 
arthralgias and/or purpura; on the contrary, very severe, rapidly progressive complications 
(glomerulonephritis, sensory-motor peripheral neuropathy, non-healing skin ulcers with 
gangrene, and/or widespread vasculitis) combined therapy with immunosuppressors, 
corticosteroids, and plasma exchange is necessary (see also text).  
 
 
  
 
Fig. 3. 
The figure summarizes the therapeutic strategies in patients with cryoglobulinemic SU 
followed at our Rheumatology Unit. In all cases a thorough clinico-serological patient’s 
assessment, including the frequent comorbidities, is mandatory. In patients with SU of the 
lower limbs the possible contribution of macrovascular involvement should be also 
investigated. Systemic treatment (see fig. 2) must be decided according to activity/severity of 
the whole MCs; in all cases both systemic and local treatments should be tailored on the single 
patient’s conditions. Local management of the SU is based on the careful evaluation of the 
single lesion characteristics: size, depth, wound-bed conditions, and presence of granulation 
tissue, exudates, necrosis, and/or infection. Therefore, an accurate sharp and/or surgical 
debridement represents the most important step of SU local management, with the supportive 
use of active medications and in the more severe cases of growth factors and/or skin grafting. 
Besides the treatment of chronic background pain, local management of SU requires the use of 
analgesic drugs in order to control the procedural pain. This latter is crucial to obtain an 
effective SU debridement, which in the presence of very severe lesions may require additional 
systemic analgesic therapy (see text). 
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Tab. 1. 
Demographic and clinico-serological fetaures of our 126 MCs patients
%
Patients no 126
M/F 24/102
Mean age (years ±DS) 69±11,2
Disease duration (years ±DS) 7±6,9
HCV associated MC 115/126 91.26%
Cryoglobulin characterization
   Type II 88/126 70%
   Type III 26/126 20.63%
Clinical manifestations
   chronic hepatitis 69/126 54.76%
   purpura 96/126 76.19%
   weakness
   arthralgias
   vasculitic skin ulcers 36/126 28.57%
   renal involvement 24/126 1904.00%
   peripheral neuropathy 85/126 6746.00%
   B cell NHL 16/122 12.69
Table
Tab. 2.  Clinical fetaures and treatments of 36 MCs patients with vasculitic skin ulcers.  
no. %
Skin ulcers localization
lower limbs (legs and/or feet) 36/36 100
lower limbs+digital ulcers 9/36 25
Infection* 29/36 81
Systemic treatment°
IFN+RIBA 8/36 22
RTX 20/36 55.5
CPX 8/36 22.2
PE 15/36 41.6
Steroids 36/36 100
low-antigen diet 36/36 100
Antibiotics 29/36 81
Analgesics 36/36 100
Combined treatments 36/36 100
Local treatment 36/36 100
MCs: mixed cryoglobulienmic syndrome (cryoglobulinemic vasculitis)
*observed at least one time during the patient's follow-up
°employed, alone or as combined therapy, at least one time during the patient's follow-up
IFN+RIBA: alpha-interferon plus ribavirin;
Table
Tab. 3. Prevalence of vasculitic SU in patients with MCs: review of the lit
MCs SU
Author, year (ref) Pts no. % 
Brouet JC, 1974 (2) 65 6.2*
Gorevic P.D, 1980 (3) 35 28.6° 
40 30°°
Invernizzi F , 1983 (4) 79 10
Cohen SJ, 1991 (30) 47 21
Ferri  C,  2004  (7) 231 22
Casato  M, 2008 (31) 64 30
Landau DA, 2010 (32) 85 4.7
Dammacco F , 2001 (8) 200 30
Perniola R, 1999 (33) 88 8
Foessel L, 2011 (34) 33 21.2
Liou Y.T 2013 (35) 96 18.8
Range 33-231 4.7-30
MCs: mixed cryoglobulinemia syndrome;  SU: skin ulcers; *4.4% leg ulcers plus 1.8% defined as distal necros
°mean prevalence reported in previous literature since 1965; °°referred to personal pts series
Table
Tab. 4.  Treatment of MCs complicated by vasculitic skin ulcers (SU): review of the literature
outcome
MCs MCs MCs SU                         Treatments  of SU
Author, year (ref) pts no. HCV+ type II/III no. (%) Systemic local H/U/W
Cohort studies 
Rieu V, 2002 (36) 40* 33 24/16 20 (40.8%)* IFN, PE, CPX, AZA, CS nd 25/nd/nd
Auzerie V, 2003 (37) 7 5 7 / 0   7  (46.6%) CPX, PE** nd 15 / 0 / 0
Zaja F, 2003 (38) 15 12 15 / 0 5 (33.3%) RTX nd 5 / 0 / 0
Sansonno D, 2003 (39) 20 20 13 / 7 7 (35%) RTX nd  3 / 2/ 2
De Vita S, 2007 (40) 28 nd 28 / 0 8 (28.5%) RTX nd 5 / nd / nd
Visentini M, 2007 (41) 6 6 6 / 0 3 (50%) RTX nd 2 / 0 / 1
Roccatello D, 2008 (42) 12 11 12 / 0 3 (25%) RTX nd 3 / 0 / 0
Saadoun D, 2008 (14) 16 16 14, / 2 2 (12.5%) RTX plus IFN-RIBA nd 2 / 0 / 0
Petrarca A, 2010 (43) 19 19 17 / 2 3 (15.7%) RTX nd 3 / 0 / 0
Dammacco F, 2010 (16) 22 22 20 / 2 5 (22.7%) RTX plus IFN-RIBA nd 4 / 0/ / 1
Visentini M, 2011 (44) 27 27 27 / 0 9 (33.3%) RTX nd 6 / nd / nd
Ferri C, 2011 (11) 87 80 73/14 24 (28%) RTX nd 15 / 2 / 7
De Vita S, 2012 (45) 57 53 57 / 0 7 (12.3%) RTX (5); non-RTX (2)° nd 6 / 1 / 0 
Case reports
Butler J.D, 1963 (46) 1 nd nd 1 chloroquine nd 0 / 1 / 0
Fontaine J.L, 1970 (47) 1 nd nd 1 nd nd 0 / 0 / 1
Riu R, 1970 (48) 1 nd nd 1 nd nd nd
Goldschmidt-Clermont JP, 1978 (49) 1 nd nd 1 none graft** 1 / 0 / 0
Geltner D, 1981 (50) 5 nd nd 3 combined therapies^ nd 3 / 0 / 0
Delaney V.B, 1984 (51) 1 nd 1 / 0 1 PE yes 1 / 0 / 0
Ralston S.H, 1988 (52) 1 nd nd 1 nd nd nd
Sundar U, 1994 (53) 1 nd 1 / 0 1 nd nd nd
Cheung N.T, 1995 (54) 3 nd nd 3 IFN 2α nd 3 / 0 / 0 
McGovern T.W, 1996 (55) 1 0 1 / 0 1 PE yes 1 / 0 / 0
Machet L, 1997 (56) 1 nd 1 / 0 1 PE+ AZA+CS nd 0 / 0 / 1
Konischi M, 1997 (57) 1 0 1 / 0 1 CS nd 1 / 0 / 0
Wisnieski JJ, 1998 (58) 1 1 1 / 0 1 IFNα2B + CPX+CS nd 0 / 0 / 1
Cavanna L, 2000 (59) 3 3 1 / 0 3 rhGM-CSF nd 3 / 0 / 0
Mahabir R.C, 2001 (60) 1 1 1 / 0 1 PE, IFNα2B, IV Ig graft 0 / 1 / 0
Ghijsels E, 2004 (61) 1 0 1 / 0 1 RTX nd 1 / 0 / 0
Ghobrial IM, 2004 (62) 1 0 1 / 0 1 RTX yes 1 / 0 / 0
Cakir O,  2005 (63) 1 0 0 / 1 1 CPX nd 1 / 0 / 0
Suárez-Amor O, 2006 (64) 4 0 2, / 2 3 CS yes   3 / 0 / 0
Hamaguchi M, 2007 (65) 1 0 1 / 0 1 Mizoribine + CS nd 1 / 0 / 0
Brownell I, 2007 (66) 1 1 0 / 1 1 none yes 1 / 0 / 0
Mironiuc A,  2008 (67) 1 1 nd 1 CS+ CPX + INFα surgery  amputated
Braun A, 2008 (68) 1 0 0 / 1 1 RTX nd 1 / 0 / 0
Tallarita T, 2009 (69) 1 1 1 / 0 1 RTX+ CS + PE nd 1 / 0 / 0
Mulder G, 2009 (70) 1 nd nd 1 nd xenograft 1 / 0 / 0
Saeed A, 2010 (71) 1 0 1 / 0 1 CS+ CYC nd 1 / 0 / 0
Da Silva Fucuta Pereira, 2010 (72) 1 1 nd 1 RTX nd 1 / 0 / 0
Roque R, 2011 (73) 1 0 1 / 0 1 CS+ CPX+PE nd 0 / 0 / 1
Ignatova TM, 2012 (74) 1 1 1 / 0 1 RTX nd 1 / 0 / 0
Zaidan M, 2012 (75) 4 2 4 / 0 3 combined therapies°° nd 2 / nd / nd
Zenone, 2013 (76) 1 0 1 / 0 1 RTX + CS nd 0 / 0 / 1
Yamazaki T, 2014 (77) 1 0 1 / 0 1 PE nd 0 / 1 / 0
Harish V, 2014 (78) 1 nd 1 / 0 1 CS+RTX+PE yes 1 / 0 / 0
MCs: mixed cryoglobulinemia syndrome; HCV: hepatitis C virus; H: healed; U: unchanged; W: worsened; nd: not done
AZA: azatipoprina; CS: corticosteroid; CPX: cyclophosphamide; PE:  Plasma Exchange; factor  
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